Inoviv develop tailored biomarker tests to identify patients and demonstrate treatment efficacy for novel therapies. Their tests support pharmaceutical companies in running successful clinical trials and in maximising access to marketed therapies.
92% of clinical trials fail to gain drug approval, this results in $25bn lost through failed clinical trials annually. Over 99% of neurodegeneration trials are unsuccessful.
Inoviv’s solution is designed to enrol the right
patients and demonstrate efficacy of new drugs, increasing clinical trial success rates by over 3X. Its biomarker tests can optimise patient enrolment into a trial by identifying patients most likely to respond to a drug, dramatically improving chances of statistically significant outcomes.
Inoviv use a proprietary technology developed in-house enabling them to measure 50+ fully calibrated molecules per biofluid sample. This enables it to develop bespoke tests specific to disease subtypes; ideal to support targeted therapies.
|Aim of funding
|HMRC Advanced Assurance received
|Envisaged investor exit
|Trade Sale or IPO
|In excess of 4-5x invested